Participated · Series A · Aug 2026

Andromeda Surgical is developing an autonomous surgery platform and is beginning clinical and commercial activity in endourology. The company is initially focusing on procedures that treat BPH, prostate cancer, bladder cancer, and kidney stones, and reports that urologists in three countries have used its platform to perform holmium laser enucleation of the prostate (HoLEP) in more than 40 patients. It has observed enucleation times as fast as 30 minutes versus a published average of about 90 minutes. The team combines surgical deeptech and healthcare expertise from organizations including Neuralink, Science Corp, Avail, and the group that launched the first autonomous truck at Starsky Robotics. Andromeda has raised $30 million to date, including a $15 million Series A, and has been cleared to launch commercially in Canada and New Zealand. The company plans to deploy its first commercial systems into hospitals in the coming months and to scale utilization while expanding into additional procedures and autonomous capabilities.

Participated · Equity · Mar 2026

KEWAZO builds robotics and AI solutions for heavy-industry material movement, with its flagship product LIFTBOT designed to replace cranes and manual handling. LIFTBOT is deployed at more than 20 sites across North America and Europe, including refineries, petrochemical plants, chemical facilities, and power plants. The company leverages operational deployments to collect structured data and is developing a broader Physical AI platform to drive further automation and transparency across industrial workflows. KEWAZO positions its technology to improve safety, increase efficiency, and enhance schedule predictability for maintenance, turnaround, and capital projects. The company has raised a total of $35 million in funding and plans to use the new capital to expand deployment capacity, extend into additional workflows, and deepen customer integrations. KEWAZO operates from Munich and Houston and counts both traditional venture investors and strategic corporate investors among its backers.

Participated · Seed · Aug 2025

Raise Robotics is a San Francisco, CA-based startup that builds robots to automate hazardous tasks on vertical construction sites. Led by Conley Oster and Gary Chen, the company provides contractors across multiple trades with versatile automated tools that perform high-risk activities such as layout, drilling, fastening, and inspection. Its robots adapt to specific site requirements and integrate into existing workflows. On August 5, 2025, Raise raised $7.8M in seed funding led by MaC Ventures, with participation from Undivided Ventures, Cybernetix Ventures, Zacua Ventures and Union Labs. The company intends to use the funds to expand operations and its development efforts.

Led · Series A · Jul 2025

Corsha offers a patented Machine Identity Provider (mIDP) that provides strong cryptographic machine identities, dynamic authentication and authorization, and automated lifecycle management for millions of machine identities. Its platform delivers continuous verification across cloud, edge, air-gapped, hybrid, and industrial environments to enable zero-trust for machine-to-machine connections. The company emphasizes securing robotics, automation, and physical AI as operational systems become increasingly autonomous and interconnected. Corsha positions its mIDP as a foundational trust layer for manufacturing APIs, protocols, and industrial autonomous systems. The recent financing will be used to accelerate scaling of the platform and expand protections across robotics and industrial autonomous systems. Corsha is backed by multiple venture firms that participated in the disclosed round. Corsha is the first and only Machine Identity Provider (mIDP) built to secure communication across operational systems and critical infrastructure. The company uses multi-factor authentication and patented identity technology to protect machine-to-machine communications and bring zero trust to operational technology environments. Corsha leverages advanced behavioral analytics to detect unusual patterns and block adversaries from accessing OT, including within defense manufacturing and other critical infrastructure. The company works with partners such as the U.S. Air Force and focuses on non-human identity for mission systems. With Booz Allen's investment, Corsha will expand its R&D lab, scale its AI and machine-learning capabilities, and advance operations in critical manufacturing environments. Corsha provides an automated multi-factor authentication solution designed specifically for machine-to-machine API traffic. Its system generates one-time-use MFA credentials from a machine's dynamic identity and verifies them against a cryptographically verifiable distributed ledger, requiring a fresh credential for each API call to enable zero-trust access. The company describes its patented approach as "MFA++" and says it avoids a central secret repository by originating MFA on the machine itself. Founded in 2018 and based in Washington, D.C., Corsha secured the U.S. Air Force as its first customer in 2020, which the company cites as a strong validation. The startup has a team of about 10 employees and is on a rapid hiring spree. After closing a $12 million Series A, Corsha plans to expand its go-to-market efforts in the enterprise. Corsha develops an API security platform that provides enterprises security, visibility, and control for data in motion as it moves through APIs, offering a dynamic, fully automated multi-factor authentication (MFA) solution for API traffic with no human user involved. The platform leverages a private, permissioned distributed ledger network (DLN) to build dynamic machine identities and secure machine-to-machine communication. Corsha's solution is Kubernetes- and cloud-native, highly scalable, platform-agnostic, and available either as a cloud-managed service or for full self-hosting. The company announced it will use NSF SBIR Phase I grant funding to advance its DLN technology to achieve greater scale and performance. The article notes the SBIR Phase I program awards up to $256,000 and makes recipients eligible to apply for Phase II funding (up to $1,000,000) and potential additional matching funds (up to $500,000) with qualifying third-party investment or sales.

Participated · Equity · Jul 2025

Dash Bio has developed a first-in-industry bioanalysis platform that combines a 24,000-square-foot GLP laboratory, robotics, and a proprietary laboratory operating system to productize assays including ELISA, MSD, qPCR, ddPCR, and LC-MS. The platform emphasizes speed, automation, transparent fixed pricing, and end-to-end digital traceability, returning preclinical sample results in days rather than months. Since launching go-to-market efforts roughly nine months ago, Dash has secured contracts with over 30 customers, including four top-15 global pharmaceutical companies. Financially, the company has raised a total of $47.5 million following its $30 million Series A led by Oak HC/FT. Dash plans to use new funding to scale commercial operations, expand its assay menu and lab capacity, move into new categories, and continue developing its proprietary software. The company was founded by Dave Johnson (CEO), Ander Tallett (COO), and Ely Porter (CSO).